Bitcoin Dispute Sparks Corporate Coup at Apimeds Pharmaceuticals

SEOUL, South Korea – March 25, 2026 – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has been plunged into a full-blown corporate governance crisis, as its majority shareholders executed a swift and decisive removal of the company's entire board and top executives. The move, which the ousted leadership has decried as an illegal maneuver, sets the stage for a high-stakes legal battle in Delaware courts, with the ownership of 1000 bitcoin, worth an estimated $70 million, at the heart of the conflict.

The dramatic shakeup occurred on March 20, when South Korean entities Inscobee Inc. and Apimeds, Inc. (Apimeds Korea), who collectively control over two-thirds of the company's voting power, delivered a written consent action to summarily dismiss the board. This was immediately followed by the appointment of a new, smaller board and a new Chief Executive Officer, effectively seizing control of the US-based pharmaceutical company.

This aggressive power play is being fiercely contested by the company’s recently acquired, wholly-owned subsidiary, MindWave Innovations Inc., which has threatened imminent legal action to invalidate the takeover. The public dispute has thrown the company's leadership, strategic direction, and stock stability into disarray.

A Swift and Decisive Takeover

Acting with overwhelming shareholder authority, Inscobee and Apimeds Korea initiated the corporate overhaul via a stockholder written consent, a mechanism permitted under Delaware law. The action immediately removed directors Elona Kogan, Jakap Koo, Carol O’Donnell, and Dr. Bennett Weintraub.

In their place, the majority shareholders appointed a new three-person board consisting of Mr. Youngjik Cho, Mr. Minguk Ji, and Mr. Junyoung Yu. The newly constituted board wasted no time in consolidating power. Their first acts included reducing the board size to three, ousting Chief Executive Officer Dr. Vin Menon and Chief Financial Officer Erick Frim, and appointing one of their own, Mr. Youngjik Cho, as the new CEO.

Inscobee and Apimeds Korea defended their actions as a necessary exercise of shareholder rights under Section 141(k) of the Delaware General Corporate Law (DGCL), which allows for the removal of directors with or without cause by a majority of shareholders. In a statement released today, they asserted that their actions were “squarely outside the scope” of any prior agreements and that they had not waived their fundamental rights under the DGCL.

The Legal Counter-Offensive

The deposed leadership, speaking through the MindWave subsidiary, has fired back, labeling the boardroom coup as “void and without legal effect.” On March 24, MindWave issued an unauthorized press release on behalf of Apimeds, alleging that the majority shareholders breached a critical “Stockholder Support and Lock-Up Agreement” dated December 1, 2025.

According to MindWave, this agreement, signed in connection with its merger with Apimeds, granted Apimeds an “irrevocable proxy” over a significant block of Inscobee’s shares. MindWave contends that Inscobee illegally used these proxied shares to reach the majority threshold needed for the written consent. Without those shares, the action would fail.

The former leadership has announced its intention to file for an emergency action in the Delaware Court of Chancery to nullify the consent and seek a Temporary Restraining Order. They argue that the pre-existing board remains the validly seated authority and have notified the company's transfer agent and the NYSE American of the ongoing dispute, creating a state of corporate limbo.

The $70 Million Bitcoin Black Box

The catalyst for this extraordinary conflict appears to be a dispute over digital assets that were central to the recent merger that brought MindWave into the Apimeds fold. The majority shareholders claim that despite repeated requests, they were unable to obtain “satisfactory information” from MindWave regarding the validity of its ownership of 1000 bitcoin.

At current market rates, 1000 bitcoin represents an asset value fluctuating between $60 million and $75 million, a substantial sum that was a “crucial consideration” in the merger. The inability to verify ownership and control of such a significant, volatile asset appears to have shattered the trust between the company’s management and its controlling shareholders.

This situation highlights the growing pains of integrating digital assets into traditional corporate finance and M&A. Verifying cryptocurrency ownership involves complex technical and security due diligence, including confirming control of private keys and ensuring the assets are free from liens or illicit history. The claim of “unsatisfactory information” suggests a fundamental failure in this due diligence process, leading to the current power struggle.

An Uncertain Path Forward

The turmoil has left Apimeds Pharmaceuticals in a precarious position. The company's stock (APUS) has seen increased volatility, and the new board has already moved to delay a previously announced 1-for-10 reverse stock split, signaling an immediate shift in financial strategy.

Further muddying the company's direction, the new leadership has announced non-binding joint venture memorandums of understanding to expand into Korean cosmetics, K-culture photo booths, and e-commerce. This sharp pivot away from its core biopharmaceutical mission—developing non-opioid pain therapeutics—raises profound questions about the company's future identity and business model under its new Korean leadership.

With two factions claiming control and a legal showdown looming in Delaware, the future of Apimeds Pharmaceuticals US, Inc. is uncertain. The outcome will not only determine the company’s leadership but may also serve as a cautionary tale for the corporate world as it continues to grapple with the complexities and risks of the digital asset economy.